T 3165/19 (PCSK9 antibody for reducing cardiovascular risk/SANOFI) of 09.01.2023
- European Case Law Identifier
- ECLI:EP:BA:2023:T316519.20230109
- Date of decision
- 9 January 2023
- Case number
- T 3165/19
- Petition for review of
- -
- Application number
- 15712241.7
- IPC class
- C07K 16/40A61P 9/00A61K 39/395
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Methods for reducing cardiovascular risk
- Applicant name
- Sanofi Biotechnology
Regeneron Pharmaceuticals, Inc. - Opponent name
- -
- Board
- 3.3.08
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 111(1)European Patent Convention Art 56Rules of procedure of the Boards of Appeal 2020 Art 011Rules of procedure of the Boards of Appeal 2020 Art 013(2)
- Keywords
- Inventive step - reasonable expectation of success (no)
Amendment after summons - change of case (no)
Remittal - special reasons for remittal (yes) - Catchword
- -
- Cited cases
- T 0239/16
- Citing cases
- T 0136/24
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the examining division for further prosecution.